HC Wainwright & Co. Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has downgraded Lyell Immunopharma (NASDAQ:LYEL) from Buy to Neutral and lowered the price target from $6 to $1.
June 27, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. has downgraded Lyell Immunopharma from Buy to Neutral and significantly lowered the price target from $6 to $1.
The downgrade from Buy to Neutral and the drastic reduction in the price target from $6 to $1 by HC Wainwright & Co. is likely to negatively impact investor sentiment and the stock price of Lyell Immunopharma in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100